Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell linesclues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma

European Journal of Cancer

Volumn 36, Issue 9, 2000, Pages 1171-1179

  Gerharz, C D ^a   Ramp, U ^a   Reinecke, P ^a   Schardt, C ^a   Friebe, U ^a   Dejosez M ^a   Nitsch, T ^a   Gabbert, H E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Epithelioid sarcoma; FGF; PDGF; TGF ; TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIOID SARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, NORTHERN; CELL COMMUNICATION; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER; SARCOMA; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0034077283     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00053-8     Document Type: Article

References (34)

1. Chase D.R., Enzinger F.M. Epithelioid sarcoma. Diagnosis, prognostic indicators and treatment. Am. J. Surg. Pathol. 9:1985;241-263.
2. Gerharz C.D., Moll R., Meister P., Knuth A., Gabbert H.E. Cytoskeletal heterogeneity of an epithelioid sarcoma with expression of vimentin, cytokeratins and neurofilaments. Am. J. Surg. Pathol. 14:1990;274-283.
3. El-Naggar A.K., Garcia G.M. Epithelioid sarcoma. Flow cytometric study of DNA content and regional DNA heterogeneity. Cancer. 69:1992;1721-1728.
4. Ishida T., Oka T., Matsushita H., Macinami R. Epithelioid sarcoma. an electron-microscopic, immunohistochemical and DNA flow cytometric analysis Virch. Arch. A Pathol. Anat. 421:1992;401-408.
5. Sonobe H., Furihata M., Iwata J.et al. Morphological characterization of a new human epithelioid sarcoma cell line, ES020488, in vitro and in vivo. Virch. Arch. B Cell. Pathol. 63:1993;219-225.
6. Evans H.L., Baer S.C. Epithelioid sarcoma. a clinicopathologie and prognostic study of 26 cases Semin. Diag. Pathol. 10:1993;286-291.
7. Halling A.C., Wollan P.C., Pritchard D.J.et al. Epithelioid sarcoma. a clinico-pathologic review of 55 cases Mayo. Clin. Proc. 71:1996;636-642.
8. Ross H.M., Lewis J.J., Woodruff J.M., Brennan M.F. Epithelioid sarcoma. clinical behaviour and prognostic factors of survival Ann. Surg. Oncol. 4:1997;491-495.
9. Brinkmann U., Pastan I. Immunotoxins against cancer. Biochem. Biophys. Acta. 1198:1994;27-45.
10. Gusterson B., Cowley G., Mcilhinney J.et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int. J. Cancer. 36:1985;689-693.
11. Reeves B., Fisher C., Smith S.et al. Ultrastructural, immunocytochemical and cytogenetic characterization of a human epithelioid sarcoma cell line (RM-HS1). J. Natl. Cancer Inst. 78:1987;7-18.
12. Gerharz C.D., Moll R., Ramp U.et al. Multidirectional differentiation in a newly established human epithelioid sarcoma cell line (GRU-1) with co-expression of vimentin, cytokeratins and neurofilament proteins. Int. J. Cancer. 45:1990;143-152.
13. Engers R., Gerharz C.D., Moll R.et al. Interclonal heterogeneity in a human epithelioid-sarcoma cell line (GRU-1). Int. J. Cancer. 59:1994;548-553.
14. Engers R., Van Roy F., Heymer T. Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumor necrosis factor alpha. Br. J. Cancer. 73:1996;491-498.
15. Engers R., Gerharz C.D., Donner A.et al. In vitro invasiveness of human epitheloid-sarcoma cell lines. association with cell motility and inverse correlation with the expression of tissue inhibitor of metalloproteinases Int. J. Cancer. 80:1999;406-412.
16. Reinecke P., Knopf C., Schmitz M., Schneider E.M., Gabbert H.E., Gerharz C.D. Growth inhibitory effects of paclitaxel (Taxol®) on human epithelioid sarcomas in vitro: heterogeneity of response and the multidrug resistance phenotype. Cancer. 88:2000;1614-1622.
17. Pusztal L., Lewis C.E., Lorenzen J., Mcgee O.D. Growth factors. regulation of normal and neoplastic growth J. Pathol. 169:1993;191-201.
18. Chirgwin J.M., Przybyla A.E., Macdonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
19. 1 resistance. an important progression factor in human renal cell carcinoma Lab. Invest. 76:1997;739-749.
20. Masui H., Kawamoto T., Sato D.et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44:1984;1002-1007.
21. Mosman T. Rapid colorimetric assay for cellular growth and survival. application to proliferation and cytotoxicity assays J. Immunol. Meth. 65:1983;55-64.
22. Carpenter G, Wahl MI. The epidermal growth factor family. In Sporn MB, Roberts AB, eds. Peptide Growth Factors and their Receptors. I. Handbook of Experimental Pharmacology. Berlin, Springer, 1990, 69-172.
23. Folkman I., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447.
24. Yudok K., Matsui H., Kanamori M.et al. Effects of epidermal growth factor on invasiveness through the extracellular matrix in high- and low-metastatic clones of RCT sarcoma in vitro. Jpn. J. Cancer Res. 85:1994;63-71.
25. Heldin C.H., Westermark B. Platelet-derived growth factor. mechanism of action and possible in vivo function Cell Regulation. 1:1990;555-566.
26. Forsberg K., Valyi-Nagy I., Heldin C.H.et al. Platelet-derived growth factor (PDGF) in oncogenesis. development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB Proc. Natl. Acad. Sci. USA. 9:1993;393-397.
27. Biard A., Böhlen P. Fibroblast growth factors. Sporn M.B., Roberts A.B. Peptide Growth Factors and their Receptors. I. Handbook of Experimental Pharmacology. 1990;369-418 Springer, Berlin.
28. Roche H., Julia A.M., Jozan S.et al. Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2). Int. J. Cancer. 54:1993;663-668.
29. Roberts A.B., Sporn M.B. The transforming growth factor-beta. Sporn M.B., Roberts A.B. Peptide Growth Factors and their Receptors. I. Handbook of Experimental Pharmacology. 1990;419-472 Springer, Berlin.
30. Kekow J., Wiedemann G.J. Transforming growth factor beta. a cytokine with multiple actions in oncology and potential clinical applications Int. J. Oncol. 7:1995;1427-1432.
31. Barnard J.A., Lyons R.M., Moses H.L. The cell biology of transforming growth factor beta. Biochem. Biophys. Acta. 1032:1990;79-87.
32. Wrana J.L., Attisano L., Wieser R.et al. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
33. Jachimczak P., Bogdahn U., Schneider J.et al. The effect of transforming growth factor β-specific phosphorothioate-anti-sense oligo deoxynucleotides in reversing immunosuppression in malignant glioma. J. Neurosurg. 78:1993;944-951.
34. 1 on in vitro angiogenesis. Exp. Cell. Res. 204:1993;356-363.